Effects of Variables on the Half-life Using the Weight Adjusted Approach, in the Respective Model for the Respective Antibody
| Variable . | PT . | PRN . | FHA . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MATAB 5 . | MATAB 6 . | MATAB 5 . | MATAB 6 . | MATAB 5 . | MATAB 6 . | |||||||
| LME . | LR . | LME . | LR . | LME . | LR . | LME . | LR . | LME . | LR . | LME . | LR . | |
| Study group, terma | − | − | − | − | − | − | ||||||
| IBVD | + | + | − | |||||||||
| AB mother | − | − | − | − | − | |||||||
| First child, yes | − | − | − | |||||||||
| Age mother at delivery | − | |||||||||||
| Days before or after expected date of delivery | − | |||||||||||
| Sex, female | + | |||||||||||
| Variable . | PT . | PRN . | FHA . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MATAB 5 . | MATAB 6 . | MATAB 5 . | MATAB 6 . | MATAB 5 . | MATAB 6 . | |||||||
| LME . | LR . | LME . | LR . | LME . | LR . | LME . | LR . | LME . | LR . | LME . | LR . | |
| Study group, terma | − | − | − | − | − | − | ||||||
| IBVD | + | + | − | |||||||||
| AB mother | − | − | − | − | − | |||||||
| First child, yes | − | − | − | |||||||||
| Age mother at delivery | − | |||||||||||
| Days before or after expected date of delivery | − | |||||||||||
| Sex, female | + | |||||||||||
+ indicates an increase in the half-life, ie, decreasing the speed of decay, while − indicates a negative effect on the half-life, ie, increasing the speed of decay. For continuous covariates the effect references to an increase in the respective variable. For factors, the effect references to the level in parentheses compared to the reference level.
Abbreviations: AB, antibodies; IBVD, Interval between vaccination and delivery; FHA, filamentous hemagglutinin; LR, linear regression model; LME, linear mixed effects model; PRN, pertactin; PT, pertussis toxin.
aOnly available in MATAB 6.
Effects of Variables on the Half-life Using the Weight Adjusted Approach, in the Respective Model for the Respective Antibody
| Variable . | PT . | PRN . | FHA . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MATAB 5 . | MATAB 6 . | MATAB 5 . | MATAB 6 . | MATAB 5 . | MATAB 6 . | |||||||
| LME . | LR . | LME . | LR . | LME . | LR . | LME . | LR . | LME . | LR . | LME . | LR . | |
| Study group, terma | − | − | − | − | − | − | ||||||
| IBVD | + | + | − | |||||||||
| AB mother | − | − | − | − | − | |||||||
| First child, yes | − | − | − | |||||||||
| Age mother at delivery | − | |||||||||||
| Days before or after expected date of delivery | − | |||||||||||
| Sex, female | + | |||||||||||
| Variable . | PT . | PRN . | FHA . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MATAB 5 . | MATAB 6 . | MATAB 5 . | MATAB 6 . | MATAB 5 . | MATAB 6 . | |||||||
| LME . | LR . | LME . | LR . | LME . | LR . | LME . | LR . | LME . | LR . | LME . | LR . | |
| Study group, terma | − | − | − | − | − | − | ||||||
| IBVD | + | + | − | |||||||||
| AB mother | − | − | − | − | − | |||||||
| First child, yes | − | − | − | |||||||||
| Age mother at delivery | − | |||||||||||
| Days before or after expected date of delivery | − | |||||||||||
| Sex, female | + | |||||||||||
+ indicates an increase in the half-life, ie, decreasing the speed of decay, while − indicates a negative effect on the half-life, ie, increasing the speed of decay. For continuous covariates the effect references to an increase in the respective variable. For factors, the effect references to the level in parentheses compared to the reference level.
Abbreviations: AB, antibodies; IBVD, Interval between vaccination and delivery; FHA, filamentous hemagglutinin; LR, linear regression model; LME, linear mixed effects model; PRN, pertactin; PT, pertussis toxin.
aOnly available in MATAB 6.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
